The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2020
| Jurisdiction | UK Non-devolved |
| Citation | SI 2020/559 |
| Year | 2020 |
2020 No. 559
Dangerous Drugs
The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2020
Made 1st June 2020
Laid before Parliament 3rd June 2020
Coming into force in accordance with regulation 1(1)
The Secretary of State makes the following Regulations in exercise of the powers conferred by sections 7(1)(a) and 31(1)(a) of the Misuse of Drugs Act 19711. In accordance with section 31(3) of that Act, the Secretary of State has consulted with the Advisory Council on the Misuse of Drugs.
Citation, commencement and extent
1.—(1) These Regulations may be cited as the Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2020 and come into force on the 21st day after the day on which they are laid before Parliament.
(2) These Regulations extend to England and Wales and Scotland.
Amendment of the Misuse of Drugs Regulations 2001
2.—(1) The Misuse of Drugs Regulations 20012are amended as follows.
(2) In regulation 2 (interpretation), in the definition of “cannabis-based product for medicinal use in humans”3, for “Schedule 4 applies” substitute—
“Schedule 4, or paragraph 10 of Schedule 5, applies”.
(3) In paragraph 1(a) of Schedule 1 (controlled drugs subject to the requirements of regulations 14, 15, 16, 18, 19, 20, 23, 26 and 27), for “Cannabinol derivatives not being dronabinol or its stereoisomers” substitute—
“Cannabinol derivatives not being—
dronabinol or its stereoisomers; or
the substance specified in paragraph 10 of Schedule 5”.
(4) In Schedule 5 (controlled drugs excepted from the prohibition on importation, exportation and possession and subject to the requirements of regulations 24 and 26), after paragraph 9 insert—
“10. A liquid formulation—
(a) containing cannabidiol obtained by extraction and purification from cannabis;
(b) where the concentration of—
delta-9-tetrahydrocannabinol is not more than 0.1 milligram per millilitre; and
cannabidiol is 95-105 milligrams per millilitre;
(c) which is presented in a bottle, as an oral solution for oral administration; and
(d) which was approved for marketing by the European Commission on 19th September 2019. ”.
Kit Malthouse
Minister of State
Home Office
1st June 2020
EXPLANATORY NOTE
(This note is not part of the Regulations)
These Regulations amend the Misuse of Drugs Regulations 2001 ( S.I. 2001/3998) to provide for a specified...
To continue reading
Request your trial